<DOC>
	<DOCNO>NCT01756885</DOCNO>
	<brief_summary>Upwards 33-50 % cancer patient smoke prior diagnosis continue smoke follow diagnosis treatment . With medical advance cancer care yield grow constituency cancer survivor , address nicotine dependence population priority . While PHS guideline recommend acute treatment duration approve medication tobacco use , extend duration treatment beyond standard treatment duration significantly increase quit rate , reduces risk relapse , promote recovery abstinence follow lapse . Varenicline may particularly effective cancer patient give drug 's beneficial effect affect cognition . In trial , 374 cancer patient randomize standard varenicline treatment ( 12 week active + 12 week placebo ) extend varenicline treatment ( 24 week active ) . The investigator hypothesize 1 ) Extended varenicline therapy increase 24- 52-week biochemically-confirmed abstinence versus standard varenicline treatment , 2 ) Quality life rat high extended therapy group versus standard therapy group , significant difference group term severe side effect , 3 ) Improved affect reduce cognitive impairment mediate effect extend therapy quit rate .</brief_summary>
	<brief_title>Extended Varenicline Treatment Smoking Among Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>1 . 18 year age old selfreport smoke least 5 cigarette ( menthol nonmenthol ) per day , average , last 6 month . 2 . Current cancer diagnosis ( site ) diagnosis within past 5 year . 3 . Karnofsky Score &gt; 50 ECOG Performance Status score &lt; 2 within 6 month enrollment . 4 . Able use varenicline safely , base medical evaluation include medical history physical examination , psychiatric evaluation . 5 . Residing geographic area least 12 month . 6 . Women childbearing potential ( base medical history physical exam ) must consent use medically accept method birth control ( e.g. , condoms spermicide , oral contraceptive , DepoProvera injection , contraceptive patch , tubal ligation ) abstain sexual intercourse time take study medication least one month medication period end . 7 . Able communicate fluently English . 8 . Capable give write informed consent , include compliance requirement restriction list combined consent/HIPAA form . Smoking Behavior 1 . Current enrollment plan enroll another smoking cessation program next 12 month . 2 . Regular ( daily ) use chew tobacco , snuff , snus , cigar , cigarillo , pipe . 3 . Current use plan use nicotine substitute ( gum , patch , lozenge , ecigarette ) smoke cessation treatment next 12 month . 1 . Note : Once participant find eligible study , tell refrain use nicotine replacement therapy ( NRT ) duration study . If subject report isolate ( nondaily ) instance NRT use study , may permit continue . Alcohol/Drug Exclusion Criteria 1 . Diagnosis substance abuse dependence unstable past year . 2 . Positive urine drug screen ( cocaine , opioids , methamphetamine ) Intake Session ( unless take opiate pain management ) . 3 . Breath Alcohol Concentration ( BrAC ) assessment great equal 0.01 Intake Session . 4 . Current alcohol consumption exceed 25 standard alcoholic drinks/week . Medication Exclusion Criteria Current use recent discontinuation ( within last 14 day ) follow medication : 1 . Other smoke cessation medication ( e.g . Zyban , Wellbutrin , Wellbutrin SR , Chantix ) . Note : Once participant find eligible study , instruct use smoke cessation medication provide study staff . If subject report isolate ( nondaily ) instance use nonstudy smoke cessation medication , study physician PI evaluate situation determine safe subject continue participation . 2 . Antipsychotic medication . 3 . Bipolar Disorder medication . Medical Exclusion Criteria 1 . Women pregnant , plan pregnancy within next 12 month , lactate . 2 . History epilepsy seizure disorder ( history seizure require Study Physician approval ) . 3 . History kidney disease , include transplant . 4 . Uncontrolled hypertension ( SBP &gt; 160 DBP &gt; 100 ) . . Note : If participant present blood pressure great 160/100 session occur Week 0 ( PreQuit ) point treatment period , provide with/able continue medication unless study physician grant approval . 5 . History heart disease , stroke MI , unstable angina , abnormal heart rhythm , tachycardia ( stable , require Study Physician approval ) . 6 . Abnormal ECG ( unless approve Study Physician ) . 7 . Any suicide risk score MINI , current suicidal ideation Columbia scale , selfreported suicide attempt . 8 . Current past diagnosis psychotic bipolar disorder , determine selfreport &amp; MINI . 9 . Current diagnosis unstable untreated major depression , determine selfreport &amp; MINI ( eligible stable &gt; 30 day ) . 10 . Previous allergic reaction varenicline . General Exclusion Criteria 1 . Any medical condition concomitant medication could compromise subject safety treatment , determine Principal Investigator and/or Study Physician . 2 . Inability provide inform consent complete study task determine Principal Investigator and/or Study Physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Smoking cessation</keyword>
	<keyword>Nicotine dependence</keyword>
	<keyword>Varenicline</keyword>
	<keyword>Chantix</keyword>
	<keyword>Cancer</keyword>
</DOC>